NEURALAGENT
3.6.2024 10:01:27 CEST | Business Wire | Press release
Airbus Defence and Space, a leader in the aerospace industry, and NeuralAgent, an innovative AI start-up, have signed two contracts that will help shape the Future Combat Air System (FCAS) programme. This tri-national programme led by the Ministries of Defence from France, Germany and Spain marks a significant step forward in strengthening European Defence Systems, notably through cutting-edge artificial intelligence. This partnership between Airbus and NeuralAgent will contribute to the FCAS’ Combat Cloud, as part of the global phase 1B contract.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530772952/en/
Figure 1: Signing Ceremony, People from left to right, Jennifer Klaschka- Marketing and Operations at NeuralAgent, Dr. -Ing Onur Deniz CEO at NeuralAgent, Dirk Sprünken Procurement at Airbus, Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus, Luis Mager – Procurement at Airbus (Photo: Business Wire)
The partnership focuses on bridging the innovation gap with an AI-defined, non-jammable, resilient, and self-organizing network and system architectures in the air, on the ground or in space. The aim is to automate and optimize the response times of an unlimited number of combat nodes, reducing them to real time or milliseconds. This initiative will leverage Airbus Defence and Space's advanced infrastructure and NeuralAgent’s cutting-edge decentralized AI technology to deliver redundant, explainable, and high-performant collaborative Agents under dynamic environments. This aims to outperform costly central AI-Approaches with a single point of failure against jamming. Together, they seek to transform defense capabilities with unprecedented and distributed autonomous intelligence of large number of combat nodes.
Dr. -Ing Onur Deniz, CEO of NeuralAgent, emphasized the importance of this collaboration: "This contract is a pivotal achievement for NeuralAgent as it allows us to not only redefine the future of AI-defined Secure and Resilient Networks through our foundational AI-Agent Models but also extends our reach into dual-use cases for commercial industries from space to ground, supporting scalable innovation across the EU."
Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus Defence and Space, highlighted the benefits of this partnership: "Working with disruptive AI start-ups such as NeuralAgent, will propel our innovation efforts and help us stay ahead with the latest AI trends. This collaboration will enhance our capabilities in both legacy and future systems, ensuring we remain at the forefront of technological advancements."
This strategic partnership between Airbus Defence and Space and NeuralAgent aims to transform European defense AI capabilities, showcasing their commitment to innovation and leadership in the EU's biggest defense project.
About Airbus Defence and Space
Airbus Defence and Space is a division of Airbus Group responsible for defence and aerospace products and services. The company is a leader in designing, developing, and manufacturing military aircraft, space systems, and connected intelligence systems and services.
About NeuralAgent
NeuralAgent is an AI start-up specializing in the development of Decentralized AI-Agent Foundation Models for distributed autonomous intelligence and shaping the future of Telecoms, Mobility, NewSpace, Robotics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530772952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom